Diabetic Foot Ulcers (DFU)

Pathophysiology & Risk Factors

Diabetic foot ulcers (DFUs) represent a complex intersection of peripheral neuropathy, peripheral arterial disease (PAD), and repetitive trauma. Sensory neuropathy diminishes protective sensation, allowing unrecognized microtrauma to progress to full-thickness tissue breakdown. Motor neuropathy alters foot biomechanics, creating high-pressure zones (e.g., metatarsal heads, hallux) prone to callus formation and underlying tissue necrosis. Autonomic neuropathy reduces sudomotor function, resulting in dry, fissured skin that serves as an entry portal for pathogens.

Concurrent PAD, present in up to 50% of DFU patients, exacerbates ischemia and impairs leukocyte delivery, antibiotic penetration, and nutrient supply to the wound margin. The chronic inflammatory microenvironment of a DFU is characterized by elevated matrix metalloproteinases (MMP-2, MMP-9), decreased growth factor bioavailability, and senescent fibroblast accumulation. This "stalled" wound bed resists conventional moist wound therapy and sharp debridement, necessitating advanced interventions to reset the healing cascade.

Wagner & UT Classification Systems

Standardized grading guides prognosis, treatment intensity, and referral urgency.

Wagner-Meggitt Classification

• Grade 0: Intact skin, pre-ulcerative lesion (callus, erythema, deformity).
• Grade 1: Superficial ulceration, partial or full thickness.
• Grade 2: Deep ulceration extending to tendon, capsule, or bone (no abscess/osteomyelitis).
• Grade 3: Deep ulceration with abscess, osteomyelitis, or joint sepsis.
• Grade 4: Gangrene of forefoot or heel.
• Grade 5: Extensive gangrene involving most of the foot.

University of Texas (UT) Classification

Stages A-D denote the presence of infection (B), ischemia (C), or both (D), providing a more robust predictor of amputation risk than depth alone.

Standard of Care (IWGDF Guidelines)

The International Working Group on the Diabetic Foot (IWGDF) evidence-based guidelines form the foundation of DFU management:

1. Offloading: Total Contact Casts (TCC) or non-removable knee-high offloading walkers are the gold standard for plantar DFUs. Removable devices are discouraged unless contraindicated (e.g., severe infection, ischemia). Offloading must continue throughout the healing phase.
2. Debridement: Regular, sharp debridement to remove hyperkeratotic edges, callus, slough, and non-viable tissue until punctate bleeding is observed. Debridement reduces bacterial bioburden and removes MMP-rich senescent cells.
3. Infection Management: Follow IDSA/IWGDF infection classification. Mild infections may be treated with oral antibiotics targeting Gram-positives; moderate-to-severe require broad-spectrum IV therapy and urgent surgical evaluation. Probe-to-bone testing and MRI are utilized for osteomyelitis diagnosis.
4. Glycemic Control: Target HbA1c < 7-8% to optimize leukocyte function and collagen synthesis, balancing against hypoglycemia risk.
5. Moist Wound Therapy: Maintain a moist wound environment with appropriate primary and secondary dressings based on exudate levels.

Despite optimal standard of care, approximately 30-40% of DFUs fail to heal within 20 weeks. For these chronic, non-healing wounds, advanced biologic therapies are indicated.

The cornerstone of DFU management is offloading. The gold standard remains the Total Contact Cast (TCC), which redistributes pressure across the entire plantar surface and reduces peak pressures at the ulcer site by up to 90%. Removable cast walkers are an alternative but require patient compliance, which is often suboptimal. Sharp debridement should

be performed regularly (weekly or bi-weekly) to remove hyperkeratotic callus, necrotic tissue, and bacterial biofilm, converting a chronic stalled wound into an acute healing wound. Vascular assessment via Toe Brachial Pressure Index (TBPI) or transcutaneous oximetry (TcPO2) is mandatory, as underlying ischemia significantly impairs healing potential and alters the risk-benefit profile of advanced therapies.

Biologics Integration

Biologics are recommended as adjunctive therapy for DFUs that demonstrate < 50% area reduction after 4 weeks of optimal standard care (offloading, debridement, infection control). The goal is to modulate the hostile wound environment, provide extracellular matrix scaffolding, and deliver regenerative cues to promote granulation and epithelialization.

Rampart Dual Layer Matrix

For DFUs with moderate-to-heavy exudate, particularly Wagner Grade 2 or UT Stage 1A/2A, Rampart Dual Layer Matrix is the primary choice. Its proprietary dual-architecture manages fluid accumulation while resisting compression, making it highly compatible with offloading devices and post-operative surgical footwear. The matrix integrates into the wound bed, acting as a temporary dermal replacement that stimulates host cell migration and neovascularization.

Application involves sharp debridement to a bleeding base, sizing the matrix to match the wound dimensions (with minimal overlap), and securing it with a non-adherent contact layer and secondary dressing. Change frequency is typically every 3-7 days, depending on exudate management.

AmnioAMP-MP

For shallow, low-exudate DFUs (Wagner Grade 1, UT Stage 1A) or wounds in the proliferation/remodeling phase where epithelial migration is the primary bottleneck, AmnioAMP-MP provides a concentrated source of growth factors and extracellular matrix proteins. It is particularly useful on wound margins, skin graft donor sites, or areas where Rampart may be too bulky.

AmnioAMP-MP can be applied directly to the wound bed or used as a wrap for digit ulcers, promoting rapid epithelialization without adding significant bulk under offloading casts.

Application Protocol Summary

• Prepare wound bed via sharp debridement and normal saline irrigation.
• Ensure hemostasis before matrix placement.
• Apply biologic matrix to wound bed, smoothing out air pockets.
• Cover with non-adherent silicone or petroleum gauze.
• Apply bulky absorbent dressing to manage exudate and secure off the matrix.
• Re-evaluate in 3-7 days; remove non-adherent secondary layers, leave adherent matrix in place until fully integrated.
• Repeat application every 2-4 weeks until 100% closure is achieved.

Long-Term Prevention

Once a DFU has healed, the risk of recurrence remains high—up to 40% within one year. Prevention strategies are therefore as critical as acute treatment. Patients must undergo comprehensive foot exams at least quarterly, including sensory testing with a 10-g monofilament and vascular assessment. Prescription of therapeutic footwear and custom orthotics reduces peak plantar pressures.

Daily self-inspection for erythema, callus formation, or minor trauma is essential. Education on glycemic control is vital, as sustained hyperglycemia impairs leukocyte function and collagen synthesis, increasing susceptibility to infection and delayed healing.

Key References

1. Bus SA, et al. "Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update)." Diabetes Metab Res Rev. 2020;36(S1):e3274.
2. Lipsky BA, et al. "2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections." Clin Infect Dis. 2016;63(1):e4-e11.
3. Armstrong DG, Boulton AJM, Bus SA.

"Diabetic foot ulcers and their recurrence." N Engl J Med. 2017;376(24):2367-2375.
4. Schumacher A. "The use of dehydrated human amnion/chorion membrane in the treatment of diabetic foot ulcers." Wounds. 2016;28(3):72-80.
5. NextGen Biologics Clinical Evidence Packets (Available upon request).
6. FDA Guidance: "Technical Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)." 2020.